Acalabrutinib is an irreversible, second-generation Bruton's tyrosine kinase (BTK) inhibitor belonging to the imidazopyrazine class. It is substituted with 4-(pyridin-2-ylcarbamoyl)phenyl, (2S)-1-(but-2-ynoyl)pyrrolidin-2-yl, and amino groups at positions 1, 3, and 8, respectively. Approved by the FDA, it is used for treating adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. It functions as a non-specific protein-tyrosine kinase inhibitor, antineoplastic agent, and apoptosis inducer. It is a secondary carboxamide, benzamide, pyridine, aromatic amine, pyrrolidinecarboxamide, imidazopyrazine, ynone, and tertiary carboxamide.
